儿童脓胸治疗策略的比较有效性:一项采用配对和网状荟萃分析的系统评价。
完整摘要 · 中文译文
背景:脓胸是儿童细菌性肺炎的一种并发症,发病率较高。有多种治疗方案可供选择,但最佳策略仍不确定。本系统评价在临床相关结局方面比较了儿童脓胸的主要治疗策略。 方法:研究方案已在PROSPERO前瞻性注册(CRD420251274193)。检索了PubMed、Embase、Scopus、Web of Science和CENTRAL数据库中2000年1月至2026年1月发表的、评估18岁以下儿童脓胸的研究。采用随机效应成对比较和频率学网络荟萃分析,比较单纯胸管引流(CT)、胸管引流+纤溶剂、电视辅助胸腔镜手术(VATS)和开胸术。主要结局为住院时间(LOS);次要结局包括治疗升级、治疗成功、并发症、死亡率和治疗相关时长。采用P评分对治疗进行排序;敏感性分析将网络限制于一线治疗组。根据研究设计选用ROBINS-I、RoB 2或JBI批判性评价清单评估偏倚风险,并采用GRADE评价证据确定性。 结果:共纳入77项研究(7,378名儿童)。与胸管引流相比,VATS(RR 0.17,95% CI 0.07-0.37)、开胸术(RR 0.13,95% CI 0.04-0.36)和胸管引流+纤溶剂(RR 0.48,95% CI 0.26-0.89)的治疗升级率更低;六项治疗升级比较中有三项的证据确定性为中等,其余为低或极低。VATS与更短的 胸膜引流(MD -2.54天,95% CI -4.64至-0.44)、抗生素使用时长(-4.95,-9.36至-0.54)和发热持续时间(-2.00,-3.97至-0.04)相关,但与住院时间(LOS)无关(-2.06,-4.57至0.45)。在配对分析中,CT+纤溶药物的升级治疗率高于VATS(RR 3.18,95% CI 1.45-6.96)。将网络限制于一线治疗组后,上述关联仍然存在;开胸术较高的网络死亡率失去统计学显著性。探索性平均P评分为0.74(VATS)、0.50(开胸术)、0.47(CT+纤溶药物)和0.29(单纯CT)。 结论:与各替代方案相比,单纯CT与更多的治疗升级相关,而VATS与更短的治疗相关持续时间相关。然而,证据以观察性研究为主,大多数比较的确定性为低至极低,而涉及开胸术的估计值对治疗线次敏感。这些关联具有假设生成性质,并不能确立治疗层级。需要开展具有明确分期和标准化升级定义的试验。 系统评价注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251274193,PROSPERO CRD420251274193。
完整摘要 · 英文原文
BACKGROUND: Empyema thoracis is a complication of bacterial pneumonia in children with substantial morbidity. Multiple treatment options are available, but the optimal strategy remains uncertain. This systematic review compared major treatment strategies for pediatric empyema thoracis across clinically relevant outcomes. METHODS: The protocol was prospectively registered with PROSPERO (CRD420251274193). PubMed, Embase, Scopus, Web of Science, and CENTRAL were searched for studies published from January 2000 through January 2026 evaluating empyema thoracis in children aged <18 years. Random-effects pairwise and frequentist network meta-analyses compared chest tube (CT) alone, CT + fibrinolytics, video-assisted thoracoscopic surgery (VATS), and thoracotomy. The primary outcome was hospital length of stay (LOS); secondary outcomes included treatment escalation, treatment success, complications, mortality, and treatment-related durations. Treatments were ranked using P-scores; a sensitivity analysis restricted the network to primary-line arms. Risk of bias was assessed using ROBINS-I, RoB 2, or the JBI critical appraisal checklist, as appropriate to study design, and certainty of evidence was evaluated using GRADE. RESULTS: Seventy-seven studies (7,378 children) were included. Compared with CT, treatment escalation was lower with VATS (RR 0.17, 95% CI 0.07-0.37), thoracotomy (RR 0.13, 95% CI 0.04-0.36), and CT + fibrinolytics (RR 0.48, 95% CI 0.26-0.89); certainty was moderate for three of six escalation comparisons and low or very low elsewhere. VATS was associated with shorter pleural drainage (MD -2.54 days, 95% CI -4.64 to -0.44), antibiotic duration (-4.95, -9.36 to -0.54), and fever duration (-2.00, -3.97 to -0.04) but not with LOS (-2.06, -4.57 to 0.45). In pairwise analysis, escalation was higher with CT + fibrinolytics than with VATS (RR 3.18, 95% CI 1.45-6.96). Restricting the network to primary-line arms preserved these associations; the higher network mortality with thoracotomy lost significance. Exploratory mean P-scores were 0.74 (VATS), 0.50 (thoracotomy), 0.47 (CT + fibrinolytics), and 0.29 (CT alone). CONCLUSIONS: CT alone was associated with more treatment escalation than each alternative, while VATS was associated with shorter treatment-related durations. However, the evidence is predominantly observational, of low to very low certainty for most comparisons, while estimates involving thoracotomy were sensitive to treatment line. These associations are hypothesis-generating and do not establish a treatment hierarchy. Trials with explicit staging and standardized escalation definitions are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251274193, PROSPERO CRD420251274193.